Chundsell Medicals AB was founded in 2007 as a spin off from Karolinska Institutet, Solna, in order to commercialize the research results of Chunde Li and his group on prostate cancer genomics. The first product: TheProstatype® Test System can assess prostate cancer aggressiveness in conjunction with currently used clinical parameters. The Prostatype® Test System measures the expression pattern of three selected and specific prostate cancer embryonic stem cell genes in tumor cell tissue specimens. These expression patterns together with a group of a selected number of known clinical parameters will help the health care professional to predict the disease outcome, the overall survival as well as cancer specific survival of patients.

Our mission at Chundsell Medicals is to improve the quality of life for patients diagnosed with cancer and their relatives. We do this by developing and marketing novel molecular diagnostics for cancer diseases, which enables prediction of prognosis of the disease and thereby simplifying the choice of the most suitable treatment for every patient.

The strategy and business idea is to market and sell in the global market a complete diagnostic system consisting of reagents for testing and quality assurance and evaluation software, adapted to the instrumentation platforms of leading Molecular Diagnostics companies. We strive to develop and produce frontline product solutions designed for optimal user compliance as well as fulfillment of the highest quality demands. Our product, the Prostatype® Test System, will meet an urgent medical need and have a positive impact on the overall health economy as well as preserve the quality of life for thousands of men each year.